AccuStem Sciences Inc. filings document formal disclosures for a clinical-stage cancer diagnostics company, including material-event reports and periodic-report compliance notices. Recent disclosures describe the MSC test, or MicroRNA Signature Classifier, as a non-invasive blood-based assay that uses a 24-microRNA plasma panel to classify pulmonary nodules as low or high risk for malignancy in LDCT screening and imaging contexts.
The filing record also includes a Form 12b-25 notification related to the company’s annual report timing. For this issuer, SEC documents center on diagnostic-test descriptions, reimbursement-related submissions, reporting obligations, and corporate information tied to its public-company status.
AccuStem Sciences Inc. reported a net loss of $485,883 for the three months ended March 31, 2026, similar to the prior year on a per-share basis at $0.03 loss per share. Research and development spending rose to $119,525, reflecting increased work on its MSC lung nodule test, while general and administrative expenses fell to $366,358.
The balance sheet remains highly leveraged, with total assets of $1.55 million and current liabilities of $5.42 million, resulting in a working capital deficit of $5.37 million and shareholder’s deficit of $3.87 million. Cash was only $12,207, and operations used $374,176 of cash in the quarter, largely funded by $395,000 in advances from a related party.
Management states there is substantial uncertainty about the company’s ability to continue as a going concern and discloses a material weakness in internal control over financial reporting due to limited accounting resources. The company expects existing cash to fund operations only until May 2026 and is actively pursuing additional equity financing.
AccuStem Sciences, Inc. is a clinical-stage diagnostics company developing genomic tests to guide cancer care decisions. Its lead products are MSC, a 24‑microRNA blood assay to classify lung nodules, and StemPrintER, a 20‑gene assay predicting distant recurrence risk in ER+/HER2‑ breast cancer.
The company targets an estimated US serviceable market of more than $5.5 billion annually for MSC and over $800 million for StemPrintER. Both assays have been validated in large clinical cohorts, including more than 5,000 patients for MSC and about 3,200 patients for StemPrintER across multiple studies.
AccuStem highlights significant risks, including substantial additional funding needs, recurring operating losses that raise doubt about its ability to continue as a going concern, reliance on licensed intellectual property from IEO/University of Milan, regulatory and reimbursement uncertainty, and dependence on third‑party laboratories, payors and partners.
Accustem Sciences Inc. submitted a Rule 12b-25 notification for a late Form 10-K covering the period ended December 31, 2025, stating the report could not be filed on time due to time constraints in compiling and reviewing required information. The company says it will file the annual report no later than 15 days after the original due date. The notification is signed by Keeren Shah, Chief Financial Officer, dated March 31, 2026.
AccuStem Sciences Inc. (ACUT) reports a key administrative step toward Medicare reimbursement for its MSC test (MicroRNA Signature Classifier), a blood-based assay that helps assess lung cancer risk in patients eligible for low-dose CT screening or with indeterminate pulmonary nodules. The MSC test analyzes 24 circulating microRNAs in plasma to classify nodules as Low or High Risk for malignancy, which may help clinicians avoid unnecessary invasive procedures for benign nodules and focus follow-up on higher-risk patients. The company has submitted an application for a local coverage determination to Novitas Solutions, a Medicare Administrative Contractor for the JL region, and Novitas has determined that the application is complete and valid and will now enter the review queue.
AccuStem Sciences (ACUT) filed its Q3 2025 10‑Q reporting continued losses and tight liquidity. The company posted a net loss of $399,897 for the quarter and $1,241,708 for the nine months ended September 30, 2025. Cash was $14,391 at quarter‑end against current liabilities of $4,484,157, resulting in a working capital deficit of $2,910,910. Management states there is substantial doubt about the company’s ability to continue as a going concern and it is actively pursuing additional equity financing.
Shares outstanding were 16,072,267 as of November 12, 2025, up from 12,100,535 at December 31, 2024, reflecting an issuance of 3,971,732 shares for $1,579,000 year‑to‑date. Related party payables totaled $3,366,503. Operating expenses rose modestly, with R&D at $72,720 and G&A at $327,177 for the quarter. The company plans to commercialize its MSC lung nodule test and StemPrintER breast cancer assay, noting an 18‑month path of lab transfer and CLIA certification milestones via its partner, EmeritusDx. Management reported a material weakness in internal control over financial reporting and plans to recruit additional accounting resources.